TMB-H
Pronunciation: T-M-B-high
Also written as: TMB-H — Tumor Mutational Burden-High
Tumor Mutational Burden-High, indicating elevated mutation density that may predict immunotherapy response.
Full Definition
TMB-H (Tumor Mutational Burden-High) refers to tumors with a high number of somatic mutations per megabase of analyzed genomic sequence, typically defined as ≥10 mutations per megabase. High TMB is associated with increased neoantigen load and potential response to immune checkpoint inhibitors. TMB-H status is used as a biomarker for immunotherapy selection across multiple cancer types. Editors must understand that TMB-H thresholds may vary between assays and cancer types, and ensure consistent hyphenation and capitalization when this biomarker status appears in clinical reports and treatment recommendations.
Usage
Usage note: Always hyphenate (TMB-H, not TMB H or TMBH). Include specific mutation count per megabase when available.
In Context
- "The patient's tumor was classified as TMB-H with 15.2 mutations per megabase." — immunotherapy biomarker report
- "TMB-H status supported the recommendation for pembrolizumab therapy." — precision oncology treatment plan